1921
Volume 89, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus–infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus–infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0264
2013-09-04
2017-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/89/3/434.html?itemId=/content/journals/10.4269/ajtmh.13-0264&mimeType=html&fmt=ahah

References

  1. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, Informal WHO Working Group on Geographic Risk for Yellow Fever; , 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11: 622632.[Crossref]
  2. Wilson ME, Chen LH, Barnett ED, , 2004. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep 6: 3442.[Crossref]
  3. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE, , 2007. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 25: 27582765.[Crossref]
  4. Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention; , 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 127.
  5. Wilder-Smith A, Hill DR, Freedman DO, , 2008. The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice. Am J Trop Med Hyg 78: 359360.
  6. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J, , 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159167.[Crossref]
  7. Gomez SY, Ocazionez RE, , 2008. Yellow fever virus 17D neutralizing antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue [in Spanish]. Rev Salud Publica (Bogota) 10: 796807.
  8. Groot H, Riberiro RB, , 1962. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 year(s) after vaccination with 17D vaccine. Bull World Health Organ 27: 699707.
  9. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, , 1981. Persistence of neutralizing antibody 30–35 year(s) after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895900.
  10. de Melo AB, da Silva M da P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET, Jr Cordeiro MT, , 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739747.[Crossref]
  11. Rosenzweig EC, Babione RW, Wisseman CL, Jr, 1963. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 12: 230235.
  12. Niedrig M, Lademann M, Emmerich P, Lafrenz M, , 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4: 867871.[Crossref]
  13. Coulange Bodilis H, Benabdelmoumen G, Gergely A, Goujon C, Pelicot M, Poujol P, Consigny PH, , 2011. Long term persistence of yellow fever neutralizing antibodies in elderly persons [in French]. Bull Soc Pathol Exot 104: 260265.[Crossref]
  14. Centers for Disease Control and Prevention, 2010. Transmission of yellow fever vaccine virus through breast-feeding–Brazil, 2009. MMWR Morb Mortal Wkly Rep 59: 130132.
  15. Kuhn S, Twele-Montecinos L, MacDonald J, Webster P, Law B, , 2011. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183: E243E245.[Crossref]
  16. Anonymous, 2011. Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol Rec 86: 3843.
  17. Kengsakul K, Sathirapongsasuti K, Punyagupta S, , 2002. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85: 131134.
  18. Mason RA, Tauraso NM, Ginn RK, O'Brien TC, Trimmer RW, , 1972. Yellow fever vaccine. V. Antibody response in maonkeys inoculated with graded doses of the 17D vaccine. Appl Microbiol 23: 908913.
  19. Mason RA, Tauraso NM, Spertzel RO, Ginn RK, , 1973. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539544.
  20. Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention; , 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 127.
  21. Julander JG, Trent DW, Monath TP, , 2011. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 29: 60086016.[Crossref]
  22. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D, , 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23: 52055211.[Crossref]
  23. Monath TP, , 2005. Yellow fever vaccine. Expert Rev Vaccines 4: 553574.[Crossref]
  24. Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL, , 2006. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24: 28432849.[Crossref]
  25. Groot H, Gast-Galvis A, , 1965. Observations on the 17 D virus vaccine against yellow fever, applied by cutaneous scarification [in Spanish]. Rev Invest (Guadalajara) 5: 525.
  26. Guerra HL, Sardinha TM, da Rosa AP, Lima e Costa MF, , 1997. Effectiveness of the yellow fever vaccine 17D: an epidemiologic evaluation in health services [in Spanish]. Rev Panam Salud Publica 2: 115120.[Crossref]
  27. Vazquez S, Valdes O, Pupo M, Delgado I, Alvarez M, Pelegrino JL, Guzmán MG, , 2003. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods 110: 179184.[Crossref]
  28. Camacho LA, Freire M da S, Leal M da L, Aguiar SG, Nascimento JP, Iguchi T, Lozana J de A, Farias RH, Collaborative Group for the Study of Yellow Fever Vaccines; , 2004. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 38: 671678.[Crossref]
  29. Tavares-Neto J, Freitas-Carvalho J, Nunes MR, Rocha G, Rodrigues SG, Damasceno E, Darub R, Viana S, Vasconcelos PF, , 2004. Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine [in Portuguese]. Rev Soc Bras Med Trop 37: 16.[Crossref]
  30. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burnas JP, Olson JG, Bedford P, Kitchener S, Monath TP, , 2005. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189197.
  31. Pfister M, Kursteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L'Age-Stehr J, Kaufhold A, Herzog C, , 2005. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 72: 339346.
  32. Suzano CE, Amaral E, Sato HK, Papaiordanou PM, Campinas Group on Yellow Fever Immunization during Pregnancy; , 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 14211426.[Crossref]
  33. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, , 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533541.
  34. Monath TP, , 2001. Yellow fever: an update. Lancet Infect Dis 1: 1120.[Crossref]
  35. Niedrig M, Kursteiner O, Herzog C, Sonnenberg K, , 2008. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 15: 177181.[Crossref]
  36. Wisseman CL, Jr Sweet BH, , 1962. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 11: 570575.
  37. Omilabu SA, Adejumo JO, Olaleye OD, Fagbami AH, Baba SS, , 1990. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria. Comp Immunol Microbiol Infect Dis 13: 95100.[Crossref]
  38. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, García-Sastre A, , 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 79: 80048013.[Crossref]
  39. Bonnevie-Nielsen V, Heron I, Monath TP, Calisher CH, , 1995. Lymphocytic 2′,5′-oligoadenylate synthetase activity increases prior to the appearance of NTAbs and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol 2: 302306.
  40. Bruyand M, Receveur MC, Pistone T, Verdiere CH, Thiebaut R, Malvy D, , 2008. Yellow fever vaccination in non-immunocompetent patients [in French]. Med Mal Infect 38: 524532.[Crossref]
  41. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, , 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29: 45444555.[Crossref]
  42. Duchet Niedziolka P, Launay O, Salmon Ceron D, Consigny PH, Ancelle T, Van der Vliet D, Lortholary O, Hanslik T, pour fe groupe GEVACCIM; , 2008. Antiviral immunization of immunocompromised adults, literature review [in French]. Rev Med Interne 29: 554567.[Crossref]
  43. Dick GW, Smithburn KC, , 1949. Immunity to yellow fever 6 year(s) after vaccination. Am J Trop Med Hyg 29: 5761.
  44. Anderson CR, Gast-Galvis A, , 1947. Immunity to yellow fever five year(s) after vaccination. Am J Hyg 45: 302304.
  45. Fox JP, Fonseca Da Cunha J, Kossobudzki SL, , 1948. Additional observations on the duration of humoral immunity following vaccination with the 17D strain of yellow fever virus. Am J Hyg 47: 6470.
  46. Veras MA, Flannery B, de Moraes JC, da Silva Teixeira AM, Luna EJ, Vaccine Coverage Survey 2007 Group; , 2010. Yellow fever vaccination coverage among children in Brazilian capitals. Vaccine 28: 64786482.[Crossref]
  47. Lopes O de S, Guimaraes SS, de Carvalho R, , 1988. Studies on yellow fever vaccine. III. Dose response in volunteers. J Biol Stand 16: 7782.[Crossref]
  48. Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, Yamamura AM, Vasconcelos PF, Oselka GW, Weckx LW, Salgado MF, Noale LF, Souza VA, , 1999. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 17: 10421046.[Crossref]
  49. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML, , 2000. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 31: 78.[Crossref]
  50. Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, Poveda JD, Michelat C, , 2004. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 18: 825827.[Crossref]
  51. Pistone T, Verdiere CH, Receveur MC, Ezzedine K, Lafon ME, Malvy D, , 2010. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res 8: 461466.[Crossref]
  52. Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, Perea W, Avokey F, Lewies RF, Veit O, , 2012. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg 106: 437444.[Crossref]
  53. Sibailly TS, Wiktor SZ, Tsai TF, Cropp BC, Ekpini ER, Adjorlolo-Johnson G, Gnaore G, De Cock KM, Greenberg AE, , 1997. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 16: 11771179.[Crossref]
  54. Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HE, Litzba N, Staub T, Hatz C, Furrer H, Swiss HIV Cohort Study; , 2009. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48: 659666.[Crossref]
  55. Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda JD, Meynard JL, Poirot JL, Fonquernie L, Girard PM, , 2012. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 59: 360367.[Crossref]
  56. Nasidi A, Monath TP, Vandenberg J, Tomori O, Calisher CH, Hurtgen X, Munube GR, Sorungbe AO, Okafor GC, Wali S, , 1993. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 87: 337339.[Crossref]
  57. Brown RE, Katz M, , 1966. Failure of antibody production to yellow fever vaccine in children with kwashiorkor. Trop Geogr Med 18: 125128.
  58. Anonymous, 1967. Effects of malnutrition on smallpox and yellow fever vaccination. Nutr Rev 25: 108110.
  59. Monath TP, Gershman M, Barret AD, Plotkin S, Orenstein W, , 2012. Yellow fever. , eds. Vaccines. Sixth Edition. Philadelphia, PA: W. B. Saunders, 870968.
  60. Groot H, Kerr JA, Sanmartin C, Vidales H, , 1959. Antibodies to yellow fever and other arthropod-borne viruses in human residents of San Vicente de Chucuri, Santander, Colombia. Am J Trop Med Hyg 8: 175189.
  61. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, III Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Hadad EK, Sékaly RP, , 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 31193131.[Crossref]
  62. Anonymous, 2010. Yellow fever fact sheet. Wkly Epidemiol Rec 85: 3336.
  63. Fox JP, Elveback L, Scott W, Gatewood L, Ackerman E, , 1995. Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 141: 187197.[Crossref]
  64. Goujon CT, Feuillie V, Coulaud P, Dupont B, Sansonetti P, , 1995. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. J Travel Med 2.
  65. Pacanowski JC, Dabrowska M, Lacombe K, , 2008. Antibody response and safety of yellow fever vaccination in HIV infected patients. Proceedings of the 48th Annual International Conference on Antimicrobial Agents and Chemotherapy, October 25–28, 2008, Washington, DC.
  66. Anonymous, 1996. Expanded programme on immunization (EPI). Inclusion of yellow fever vaccine in the EPI. Wkly Epidemiol Rec 71: 181185.
  67. Monath TP, , 2006. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot 99: 341347.
  68. Hanson H, , 1929. Observations on the age and sex incidence of deaths and recoveries in the yellow fever epidemic in the department of Lambayeque, Peru, in 1921. Am J Trop Med 9: 233239.
  69. Monath TP, Craven RB, Adjukiewicz A, Germain M, Francy DB, Ferrara L, Samba EM, N'Jie H, Cham K, Fitzgerald SA, Crippen PH, Simpson DI, Bowen ET, Fabiyi A, Salaun JJ, , 1980. Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of Orungo virus infections. Am J Trop Med Hyg 29: 912928.
  70. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, Lindstrom S, Louie JK, Christ CM, Bohm MR, Fonseca VP, Ritger KA, Kuhles DJ, Eggers P, Bruce H, Davidson HA, Lutterloh E, Harris ML, Burke C, Cocoros N, Finelli L, MacFarlane KF, Shu B, Olsen SJ, Novel Influenza A (H1N1) Pregancy Working Group; , 2009. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374: 451458.[Crossref]
  71. Ingardia CJ, Kelley L, Steinfeld JD, Wax JR, , 1999. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstet Gynecol 93: 983986.
  72. Nishioka S de A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL, , 1998. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 3: 2933.[Crossref]
  73. Cavalcanti DP, Salomao MA, Lopez-Camelo J, Pessoto MA, Campinas Group of Yellow Fever Immunization during Pregnancy; , 2007. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 12: 833837.[Crossref]
  74. Elliot M, , 1944. Yellow fever in the recently inoculated. Trans R Soc Trop Med Hyg 38: 231236.[Crossref]
  75. Ross RW, Haddow AJ, Raper AB, Trowell HC, , 1953. A fatal case of yellow fever in a European in Uganda. East Afr Med J 30: 111.
  76. Nolla-Salas J, Saballs-Radresa J, Bada JL, , 1989. Imported yellow fever in vaccinated tourist. Lancet 334: 1275.[Crossref]
  77. Tuboi SH, Costa ZG, da Costa Vasconcelos PF, Hatch D, , 2007. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998–2002. Trans R Soc Trop Med Hyg 101: 169175.[Crossref]
  78. McFarland JM, Baddour LM, Nelson JE, Elkins SK, Craven RB, Cropp BC, Chang GJ, Grindstaff AD, Craig AS, Smith RJ, , 1997. Imported yellow fever in a United States citizen. Clin Infect Dis 25: 11431147.[Crossref]
  79. Barros ML, Boecken G, , 1996. Jungle yellow fever in the central Amazon. Lancet 348: 969970.[Crossref]
  80. Bae HG, Drosten C, Emmerich P, Colebunders R, Hantson P, Pest S, Parent M, Schmitz H, Warnat MA, Niedrig M, , 2005. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol 33: 274280.[Crossref]
  81. Anonymous, 2000. Yellow fever, 1998–1999. Wkly Epidemiol Rec 75: 322328.
  82. Colebunders R, Mariage JL, Coche JC, Pirenne B, Kempinaire S, Hantson P, Van Gompel A, Niedrig M, Van Esbroeck M, Bailey R, Drosten C, Schmitz H, , 2002. A Belgian traveller who acquired yellow fever in the Gambia. Clin Infect Dis 35: e113e116.[Crossref]
  83. Centers for Disease Control and Prevention, 2002. Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. JAMA 287: 24992500.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0264
Loading
/content/journals/10.4269/ajtmh.13-0264
Loading

Data & Media loading...

  • Received : 15 May 2013
  • Accepted : 23 Jun 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error